publications

Psychometric Evaluation of Social Cognition and Behavior Measures in Children and Adolescents with Down Syndrome.

Schworer, Emily KHoffman, Emily KEsbensen, Anna J

Summary

While many of those with Down syndrome are described as socially engaged, challenges with cognition, language, and social interaction are still very common. This study looks at metrics used to assess such challenges and how such metrics should be used in DS related clinical trials. The Social Responsiveness Scale, Second Edition (SRS-2; T-scores) had the most positive results, suggesting that this measure could be appropriate for use in DS clinical trials.

Abstract

Individuals with Down syndrome (DS) are often described as socially engaged; however, challenges with social cognition, expressive language, and social interaction are also common in DS and are prospective outcomes of interest for clinical trials. The current study evaluates the psychometric properties of standardized measurements of social cognition and social behavior for potential use as outcome measures for children and adolescents with DS. Seventy-three youth ages 6 to 17 years old (M = 12.67, SD = 3.16) with DS were assessed on social cognition subtests of a neuropsychological assessment at two time points. Caregivers also completed a parent-report measure of social behavior. Measures were evaluated for feasibility, test-retest reliability, practice effects, convergent validity, and associations with broader developmental domains (i.e., age, cognition, and language). All social cognition and behavior measures met criteria for a portion of the psychometric indices evaluated, yet feasibility limitations were identified for the Developmental Neuropsychological Assessment, Second Edition (NEPSY-II) Affect Recognition subtest, and the NEPSY-II Theory of Mind subtest had problematic floor effects for percentile ranks. The Social Responsiveness Scale, Second Edition (SRS-2; T-scores) had high feasibility, moderate to excellent test-retest reliability, and no practice effects, suggesting this measure could be appropriate for use in clinical trials involving youth with DS.